EUVIMEDEUVIMED entdecken
Crossref

p53-R248W evades doxorubicin mediated cell death through collective alteration in TOP2A and CYP1A1 genes in cancer cells

Megha Mehrotra, Priti S Shenoy, Asmita Sakpal, Sourav Chakraborty, Pritha Ray

Biochemical and Biophysical Research Communications · 2026-06 · 819 · 153759

DOI: 10.1016/j.bbrc.2026.153759 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2026-06. Verfasst von Megha Mehrotra und 4 weiteren Autor:innen. Beteiligte Einrichtung: Imaging Cell Signalling & Therapeutics Lab, Advanced Centre for Treatment, Research and Education in Cancer-Tata Memorial Centre, Navi Mumbai, India;…. Hauptthemen laut MEDLINE: Doxorubicin, Tumor Suppressor Protein p53, Cytochrome P-450 CYP1A1, DNA Topoisomerases, Type II. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Government of India Department of Atomic Energy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Doxorubicin alone or in combination is widely used as first- or second-line chemotherapy in multiple solid tumors. Yet poor overall/progression-free survival and high mortality reflect the inherent Dox-resistance. Such resistance significantly limits the response to anthracycline-containing regimens. Frequent occurrence of TP53 mutations across cancers suggests that mutant-p53 may drive selective chemoresistance towards first- and second-line chemotherapeutics but the underlying mechanism remains inadequately explored. METHODS p53 hotspot mutations-R248W, R273H, R175H, R282W and wtp53 were overexpressed in p53-null ovarian (SKOV3) and gastric (KATOIII) cells. R248W mutant was also expressed in p53-null murine breast cancer (4T1) cells. MTT assay, immunoblotting and qPCR were used to assess drug sensitivity, apoptosis, autophagy and gene expression. Flow cytometry and immunofluorescence was used to assess cellular and nuclear doxorubicin levels. RESULTS p53-mutant expressing cells showed varied responses to cisplatin and doxorubicin. p53-R248W cells were sensitive to cisplatin but highly resistant to doxorubicin as measured by MTT assay and absence of PARP cleavage in multiple cancer cells. All mutants and wtp53 displayed differential degree of doxorubicin efflux. Doxorubicin-resistant p53-R248W SKOV3 cells could retain the drug, possibly due to decreased ABC transporter levels. Reduced BAX and TOP2A and hyperactivated CYP1A1/A2 levels were observed with doxorubicin-treatment in p53-R248W expressing ovarian, gastric and breast cancer cells. CONCLUSION p53-R248W confers selective doxorubicin resistance to multiple cancer cells through TOP2A suppression and CYP1A1/A2 overexpression. These findings highlight the mutation specific mechanism of doxorubicin resistance that might result in poor response and needs to be considered during treatment plan.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinTumor Suppressor Protein p53Cytochrome P-450 CYP1A1DNA Topoisomerases, Type IIPoly-ADP-Ribose Binding ProteinsHumansCell Line, TumorDrug Resistance, NeoplasmAnimalsFemaleMiceApoptosisAntibiotics, AntineoplasticMutation

Stichwörter der Autor:innen

ChemoresistanceDoxorubicinGastric cancerHigh-grade serous ovarian cancerMutant p53

Substanzen

DoxorubicinTumor Suppressor Protein p53Cytochrome P-450 CYP1A1DNA Topoisomerases, Type IIPoly-ADP-Ribose Binding ProteinsTOP2A protein, humanAntibiotics, Antineoplastic

Autor:innen und Institutionen

  • Imaging Cell Signalling & Therapeutics Lab, Advanced Centre for Treatment, Research and Education in Cancer-Tata Memorial Centre, Navi Mumbai, India; Homi Bhabha National Institute, Anushakti Nagar, Mumbai, India.
  • Imaging Cell Signalling & Therapeutics Lab, Advanced Centre for Treatment, Research and Education in Cancer-Tata Memorial Centre, Navi Mumbai, India.
  • Imaging Cell Signalling & Therapeutics Lab, Advanced Centre for Treatment, Research and Education in Cancer-Tata Memorial Centre, Navi Mumbai, India; Homi Bhabha National Institute, Anushakti Nagar, Mumbai, India. Elect…

Förderung

  • Government of India Department of Atomic Energy

Zitieren

APA

Mehrotra, M., Shenoy, P. S., Sakpal, A., Chakraborty, S., & Ray, P. (2026). p53-R248W evades doxorubicin mediated cell death through collective alteration in TOP2A and CYP1A1 genes in cancer cells. Biochemical and Biophysical Research Communications, 819, 153759. https://doi.org/10.1016/j.bbrc.2026.153759

Vancouver

Mehrotra M, Shenoy PS, Sakpal A, Chakraborty S, Ray P. p53-R248W evades doxorubicin mediated cell death through collective alteration in TOP2A and CYP1A1 genes in cancer cells. Biochemical and Biophysical Research Communications. 2026;819:153759. doi:10.1016/j.bbrc.2026.153759

BibTeX
@article{Mehrotra2026,
  author = {Mehrotra, Megha and Shenoy, Priti S and Sakpal, Asmita and Chakraborty, Sourav and Ray, Pritha},
  title = {p53-R248W evades doxorubicin mediated cell death through collective alteration in TOP2A and CYP1A1 genes in cancer cells},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2026},
  volume = {819},
  pages = {153759},
  doi = {10.1016/j.bbrc.2026.153759}
}
Kostenlos starten →